Skip to main content

Table 2 Data for the 18 illustrative technologies in Figures 2 and 3

From: Which health technologies should be funded? A prioritization framework based explicitly on value for money

Technology (indication, number of potential patients) Lives Saved Life-Prolongation Benefits Quality-of-Life (QoL) gains If this technology were not to be funded … Other important social or ethical benefits, etc Total cost (millions of shekels, annual) Quality of evidence X-factors
t1. Smoking cessation drugs (smokers, 6000) Very many: >500 lives saved Large benefits Large QoL gains Many/most patients will be able to pay for it themselves (privately) Yes 5.29 high not smoking is a personal choice
t2. Taxotere (head and neck cancer, 200) None (or not yet known) Large benefits None/very small (or not yet known) Many/most patients will not receive any treatment for condition Yes 4.6 high none
t3. Herceptin (breast cancer – adjuvant treatment, 700) Few: 1-50 lives saved Medium benefits Small QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government Yes 124 high none
t4. Elaprase (Hunter syndrome, 3) Few: 1-50 lives saved None/very small (or not yet known) Medium QoL gains Many/most patients will not receive any treatment for condition Yes 5.45 poor orphan drug
t5. Visudyne (age-related macular degeneration, 1050) None (or not yet known) None/very small (or not yet known) Large QoL gains Many/most patients will not receive any treatment for condition Yes 26.47 high none
t6. Left-ventricular assist devices (terminal heart failure, 12) Few: 1-50 lives saved Small benefits Small QoL gains Many/most patients will not receive any treatment for condition Yes 4.83 high none
t7. Statins (hypercholesterolemia, 5600) None (or not yet known) Medium benefits Medium QoL gains Many/most patients will be able to pay for it themselves (privately) Yes 16 high strategic considerations
t8. Pain relief (neuropathic pain, 14,250) None (or not yet known) None/very small (or not yet known) Large QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government Yes 46 high none
t9. Revlimid (multiple myeloma – 3rd-line treatment, 200) None (or not yet known) Medium benefits None/very small (or not yet known) Many/most patients will not receive any treatment for condition Yes 39 medium none
t10. Dental care (children, 20,000) None (or not yet known) None/very small (or not yet known) Medium QoL gains Many/most patients will not receive any treatment for condition Yes 65 high political considerations
t11. Growth hormone (short-statured children, 3900) None (or not yet known) None/very small (or not yet known) Medium QoL gains Many/most patients will not receive any treatment for condition Yes 25.6 high none
t12. Avastin [Bevacizumab] (colon cancer, 700) None (or not yet known) Medium benefits Small QoL gains Many/most patients will not receive any treatment for condition None/Very small (or not yet known) 76.27 medium none
t13. Over-active bladder drugs (urinary urge, incontinence, 21,000) None (or not yet known) None/very small (or not yet known) Large QoL gains Many/most patients will be able to pay for it themselves (privately) Yes 37 high none
t14. Fuzeon (HIV, 45) None (or not yet known) Medium benefits Small QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government None/Very small (or not yet known) 3.33 high none
t15. Long-acting insulins (diabetes, 10,000) None (or not yet known) Small benefits Medium QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government None/Very small (or not yet known) 17.83 high none
t16. Contraceptives (adolescent girls, 20,000) None (or not yet known) None/very small (or not yet known) Medium QoL gains Many/most patients will be able to pay for it themselves (privately) Yes 3.11 high socio-ethical, religious considerations
t17. Erbitux (colon cancer – for KRAS mutation negative, 210) None (or not yet known) Small benefits Small QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government None/Very small (or not yet known) 47.26 medium none
t18. Humira (psoriatic arthritis, 60) None (or not yet known) None/very small (or not yet known) Small QoL gains Many/most patients will get an alternative treatment (less effective) already funded by government None/Very small (or not yet known) 3.49 medium none